Hester Biosciences Limited (HESTERBIO) AI Stock Analysis

• Market Cap: ₹13.14B
• Dividend Yield: 0.44%
• Average Volume (3M): 308.00
• Price to Earnings (P/E): 29.3
• Beta (1Y): 0.58
• Revenue Growth: -3.84%
• EPS Growth: 86.82%
• Country: IN
• Employees: 642
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 16.98
• Shares Outstanding: 8,506,865
• 10 Day Avg. Volume: 428
• 30 Day Avg. Volume: 308
• PEG Ratio: 0.96
• Price to Book (P/B): 3.84
• Price to Sales (P/S): 3.88
• P/FCF Ratio: 27.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: ₹1,827.00 ▲(13.78% Upside)

Hester Biosciences Limited's overall stock score is primarily supported by its strong financial performance, which indicates robust revenue and profit growth. However, the technical analysis suggests bearish momentum, and the valuation indicates the stock might be overvalued. These factors contribute to a moderate overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and sustainability.

Cash Flow Management

Effective cash flow management ensures the company can fund operations, invest in growth opportunities, and maintain financial stability over time.

Profit Margins

Improving profit margins reflect enhanced operational efficiency, allowing the company to better withstand market fluctuations and maintain profitability.

Negative Factors

Debt Levels

Rising debt levels can strain financial resources, potentially limiting the company's ability to invest in growth and affecting long-term financial health.

Market Valuation Concerns

A high valuation may limit future stock price appreciation and could indicate investor expectations that may be challenging to meet, impacting long-term investor confidence.

Dividend Yield

A low dividend yield may deter income-focused investors, potentially affecting the stock's attractiveness and limiting its investor base over time.

Hester Biosciences Limited Business Overview & Revenue Model

Company Description

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates in two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for diseases, such as newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reo, marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, avian encephalomyelitis, etc. It also offers vaccines for large animals comprising Goat Pox, Peste des Petits Ruminants, Brucellosis, Mastitis, Metritis, and various infectious diseases, as well as infections, reproductive disorders, theileriosis, parasitic diseases, etc. In addition, the company provides feed supplements, such as toxin binder, trace minerals, enzyme preparation, and bypass fat; disinfectants for farms and equipment, and water sanitizers; nutrition products consisting of mineral mixtures, fertility supplements, and growth tonics; and herbal products, including growth promoters, herbal replacers for choline chloride, stress relievers and immunity boosters, respiratory stimulants, liver tonics, wound healing preparations, uterine tonics, digestive tonics and anti-bloat solutions, ectoparasiticide preparations, anti-mastitis, and anti-prolapse preparations. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.

How the Company Makes Money

Hester Biosciences generates revenue primarily through the sale of its veterinary vaccines and biological products. The company operates on a B2B model, supplying its products to farmers, veterinary clinics, and animal health distributors. Key revenue streams include the sale of various vaccines for poultry, cattle, and swine, alongside diagnostic kits and health supplements. Hester also benefits from strategic partnerships with international organizations and collaborations with research institutions that enhance its product offerings and market reach. Additionally, the company engages in export activities, which further contribute to its revenue growth by tapping into global markets.

Hester Biosciences Limited Financial Statement Overview

Summary

Hester Biosciences Limited demonstrates strong financial health across its income statement, balance sheet, and cash flow metrics. The company shows significant revenue and profit growth with improving margins, a balanced financial structure, and robust cash flow generation. However, the increase in debt should be monitored to prevent potential financial strain.

Income Statement

The company's revenue growth is robust, with consistent upward trends over the years, including a significant spike in gross profit margins. EBIT and EBITDA margins have shown improvement, indicating operational efficiency. The net profit margin has remained stable, showing consistent profitability.

Balance Sheet

The company maintains a solid equity base with a moderate debt-to-equity ratio, indicating balanced leverage. The return on equity shows steady profitability relative to shareholder equity. The equity ratio indicates a sound financial structure, but the increase in total debt requires close monitoring.

Cash Flow

Positive free cash flow growth highlights effective cash management despite significant capital expenditures. The operating cash flow to net income ratio suggests healthy cash generation. The free cash flow to net income ratio shows improvement, reflecting better cash conversion efficiency.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.13B	3.11B	3.05B	2.66B	2.35B	2.14B
Gross Profit	1.87B	2.08B	972.64M	1.89B	1.66B	1.58B
EBITDA	654.50M	649.76M	582.46M	619.20M	731.93M	700.21M
Net Income	375.94M	274.88M	188.89M	266.27M	393.20M	344.30M
Balance Sheet
Total Assets	0.00	6.53B	6.62B	6.70B	5.62B	4.11B
Cash, Cash Equivalents and Short-Term Investments	72.19M	72.19M	153.04M	148.17M	252.20M	212.69M
Total Debt	0.00	2.13B	2.44B	2.74B	2.28B	1.10B
Total Liabilities	-3.27B	3.27B	3.59B	3.81B	2.95B	1.75B
Stockholders Equity	3.27B	3.14B	2.92B	2.80B	2.60B	2.28B
Cash Flow
Free Cash Flow	0.00	439.20M	237.37M	-541.66M	-869.02M	173.11M
Operating Cash Flow	0.00	645.11M	481.34M	235.96M	88.08M	580.53M
Investing Cash Flow	0.00	-190.03M	-226.54M	-769.99M	-1.17B	-383.72M
Financing Cash Flow	0.00	-517.17M	-260.45M	417.58M	1.12B	-182.19M

Hester Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1605.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HESTERBIO, the sentiment is Negative. The current price of 1605.75 is above the 20-day moving average (MA) of 1583.82, below the 50-day MA of 1617.62, and below the 200-day MA of 1781.10, indicating a bearish trend. The MACD of -14.85 indicates Negative momentum. The RSI at 38.91 is Neutral, neither overbought nor oversold. The STOCH value of 22.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:HESTERBIO.

Hester Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HESTERBIO	61 Neutral	₹13.14B	29.26	―	0.44%	-3.84%	86.82%
SEQUENT	58 Neutral	₹48.92B	113.84	―	―	14.39%	152.14%
GUFICBIO	57 Neutral	₹31.65B	56.32	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹21.18B	21.41	―	0.49%	-0.29%	-29.04%
UNICHEMLAB	54 Neutral	₹29.28B	32.66	―	―	25.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	40 Neutral	₹19.83B	-17.95	―	0.08%	-2.81%	-444.69%

Hester Biosciences Limited Corporate Events

Hester Biosciences to Close Trading Window Ahead of December Quarter Results

Hester Biosciences Limited has announced the closure of its trading window for dealings in the company’s equity shares from 1 January 2026 until 48 hours after its financial results for the quarter and nine-month period ended 31 December 2025 are made publicly available. The move, undertaken in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct for directors, promoters, designated employees, and connected persons, is a standard governance measure aimed at preventing insider trading and reinforcing regulatory compliance and transparency for investors and other stakeholders.

Hester Biosciences Appoints New CFO to Enhance Financial Strategy

Hester Biosciences Limited has announced the appointment of Mr. Ashish Desai as the new Chief Financial Officer, effective from November 20, 2025. Mr. Desai, who previously served as the Group Finance Controller, brings over 25 years of experience in finance and accounting, and his appointment is expected to strengthen the company’s financial management and strategic initiatives.

Hester Biosciences Appoints Ashish Desai as CFO

Hester Biosciences Limited has announced the appointment of Mr. Ashish Desai as the new Chief Financial Officer, effective from November 20, 2025. Mr. Desai, who brings over 25 years of experience in finance and accounting, will transition from his current role as Group Finance Controller. This strategic appointment is expected to enhance the company’s financial management and strengthen its market position, given Mr. Desai’s extensive background in financial restructuring and cost optimization.

Hester Biosciences Announces Key Managerial Changes

Hester Biosciences Limited has announced a change in its Key Managerial Personnel (KMP) authorization as per SEBI regulations. The Board of Directors has approved the appointment of Mr. Ashish Desai as the new Chief Financial Officer and KMP, which aligns with the company’s policy on materiality disclosure. This change is expected to enhance the company’s financial management and compliance with regulatory requirements, potentially impacting its operational efficiency and stakeholder confidence.